Feasibility and Tolerability of Eribulin-Based Chemotherapy Versus Other Chemotherapy Regimens for Patients With Metastatic Triple-Negative Breast Cancer: A Single-Center Retrospective Study
February 2024
in “
Frontiers in Cell and Developmental Biology
”
Studysummary This study found that eribulin-based chemotherapy resulted in longer median progression-free and overall survival, with fewer side effects, for advanced triple-negative breast cancer patients compared to other chemotherapy options.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on frontiersin.org →